ethchlorvynol (Placidyl)

Introduction

Tradename: Placidyl. DEA-controlled substance: class 4.

Dosage

500 mg PO QHS

Tabs: 200, 500, 750 mg.

Pharmacokinetics

• extensive distribution to adipose tissue
• biphasic elimination

elimination via liver

elimination via kidney

1/2life = 10-20 hours

protein binding = 60 %

elimination by hemodialysis = -

elimination by hemoperfusion = +

elimination by peritoneal dialysis = -

Adverse effects

• dizziness
• nausea/vomiting
• hypotension
• respiratory depression, bradycardia, hypothermia with overdose

• drug adverse effects of psychotropic agents
• drug adverse effects of sedatives

Laboratory

• ethchlorvynol in specimen
  • ethchlorvynol in body fluid
    • ethchlorvynol in blood
    • ethchlorvynol in bile fluid
    • ethchlorvynol in gastric fluid
    • ethchlorvynol in serum/plasma
    • ethchlorvynol in urine

More general terms

• sedative/hypnotic (tranquilizer)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3281
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5281077
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5284556